News
Ending the guesswork in cancer care: A CEO’s vision for predictive precision oncology

By Wolfgang Hackl M.D., Founder & CEO, OncoGenomX Inc., Switzerland
During my career as an oncologist and cancer drug developer, one question haunted me more than any other: Why do some patients respond to therapy — while others, with the same diagnosis, do not?
We have innovative treatments, biomarkers, advanced lab tests, and guidelines. But far too often, despite all that science, our treatment decisions come down to educated guesswork.
As medicine evolves, so do our data — but not always our ability to act on it with precision.
That enduring gap between what we know and what we can predict inspired me to found OncoGenomX, and to build PredictionStar™, a platform designed to redefine what precision oncology truly means.
From Biomarkers to Behavior: The Missing Link
Today, most molecular cancer tests focus on eligibility: they tell us whether a tumour expresses a particular target or carries a known mutation. This is useful, but it’s only half the story.

Eligibility does not equal efficacy.
Knowing that a patient’s tumour expresses the estrogen receptor (ER), or harbours a PIK3CA mutation, doesn’t mean it will respond to hormone therapy or PI3K inhibition. It simply means those drugs might work. And in oncology, “might” is not enough.
PredictionStar™ was built to close this precision gap — by answering not just which drugs can be used, but which will actually work.
We call this Precision Drug–Tumor Matching: the ability to segregate effective from ineffective treatments by connecting genomic and phenotypic insights into a coherent tumour profile predictive of therapeutic response.
Introducing PredictionStar™: Coherent Biomarker Intelligence
PredictionStar™ is a multidimensional tumour profiling and decision-support system powered by what we term Generative Clinical Intelligence™ — the synthesis of high-quality sequencing data and AI-driven interpretation into clear, actionable clinical guidance.
Traditional assays analyse biomarkers in isolation, treating each gene mutation or expression pattern as a separate clue.
PredictionStar™ instead identifies logically connected biomarker constellations — genomic enablers that reveal which response mechanisms are active, and phenotypic differentiators how likely the tumour will respond.
This networked approach replaces fragmented snapshots with an integrated, functional map of tumour behaviour.
It provides oncologists with something they rarely get from today’s tests: confidence. In clinical modelling, PredictionStar™ has the potential to reduce overtreatment fivefold and lower the cost of achieving one year of tumour growth control by 35 per cent.
But the numbers tell only part of the story. Behind them are patients spared from unnecessary toxicity — and doctors empowered to treat with precision instead of probability.
Built on the Technology of Giants
PredictionStar™ was designed for seamless integration into modern real-world workflows, harmonized and cross-validated to ensure reliability, and reproducibility.

The platform’s pre-sequencing tumor workup is fully standardised, minimizing inter-laboratory variability that can otherwise reach 70 per cent.
From tumour processing to data interpretation, PredictionStar™ enforces the same rigorous quality in every step, producing consistent and concordant results across labs.
As far as cloud architecture optimized for medical data privacy and global scalability we are privileged to work with world class-players of the health IOT industry
(F. Gaede, Oct 2025, Nordcloud).
A Femtech Focus: Personalising Breast Cancer Therapy
While PredictionStar™ has broad oncology applications, our first focus is hormone receptor-positive breast cancer, the most prevalent form among women.
It is here that the limits of current diagnostics are most evident — and the need for predictive and prescriptive clarity is greatest.
Even within hormone-dependent breast cancer, the most favorable form of the disease, patient outcomes vary widely. Some women respond beautifully to endocrine therapy for years, while others progress rapidly.
What makes the difference? The answers are buried in the tumour’s individual response profiles — but until now, we lacked the tools to decode them. PredictionStar™ offers that decoding ability.
Our non-interventional validation study, conducted in collaboration with clinical researchers from the Veterans Affairs Medical Centers in Cincinnati, Los Angeles, and Miami, involves data from over 4,300 patients with hormone receptor-positive disease.
By correlating predicted responses with actual treatment outcomes, we aim to establish a new clinical standard for predictive accuracy.
Our roadmap includes RUO and LDT certification in 2026, FDA-IDE clearance in Q2 2027, first RUO test sales as early as Q1 2027, and clinical study use from Q3 2027 onwards.
Redefining Precision Oncology
To understand why this matters, we need to reframe what “precision” means.
Most tests today are prognostic or eligibility-based. They classify risk or confirm target presence. PredictionStar™ adds a third, transformative dimension: functional prediction. It asks, “Which therapies will this specific tumour respond to — and how strongly?”
This evolution turns diagnostics into a true decision-support tool, enabling oncologists to design treatment compositions optimized for efficacy, rather than constrained by averages.
The distinction may seem subtle, but its impact for individuals living with breast cancer is enormous: Prognostic and eligibility tests describe. PredictionStar™ guides.
Innovation Through Unity
Our strength lies in collaboration.
I’ve often said that OncoGenomX stands “on the technology of giants, powered by the ambition to transform.” That is more than a slogan — it’s our reality. We built PredictionStar™ not as an isolated product, but as a platform for partnership.
Its architecture invites integration — with hospital systems, sequencing providers, AI developers, and pharmaceutical R&D pipelines.
In the coming years, we envision PredictionStar™ evolving into a broader family of tools: PredictionStar DX™ for predictive diagnostics, PredictionStar GCI™ for data integration and generation of actionable clinical intelligence, and PredictionStar IOT™ for real-time connectivity. Each module serves the same purpose: to transform complexity into clarity.
From Data to Decisions: A Personal Reflection
At its heart, PredictionStar™ was born from empathy.
As a clinician, I saw too many patients fall through the cracks — not because we lacked treatments, but because we lacked foresight.
Data without interpretation is noise. Our mission is to turn that noise into understanding.
When I speak with oncologists today, I sense both excitement and relief: “We will no longer be limited to maybes.” “We can begin to quantify response likelihood, combine therapies more rationally, and give patients something we cannot give today: certainty”.
Technology can be transformative, but only when anchored in purpose. For OncoGenomX, that purpose is simple — to give every patient the best possible chance at lasting response.
The Road Ahead
Our journey is just beginning. We are validating, scaling, and expanding across cancer types — from breast to prostate, lung, and beyond.
But our guiding principle remains unchanged: wherever there is cancer, there is a need for precision drug–tumour matching.
The convergence of genomics, phenomics, AI, and clinical data is redefining healthcare.
PredictionStar™ is part of that transformation — proving that predictive precision is not a futuristic concept, but an attainable standard.
We owe it to patients, to clinicians, and to science itself to make that standard universal.
In Closing
When I founded OncoGenomX, I imagined a world where no cancer patient has to live with uncertainty — where treatment is guided by prediction, not probability.
Today, that world feels within reach. PredictionStar™ is more than technology. It’s a promise:
That every patient deserves clarity. That every tumour can be understood.
And that, together, we can end the guesswork in cancer care.
Contact: Dr. Wolfgang Hackl | Founder & CEO, OncoGenomX | E-Mail | LinkedIn WH | Company Webpage | LinkedIn OGX
News
Empowering women’s health with music

By Con Raso, managing director, Tuned Global
Music and movement are neurologically intertwined. Tempo influences pace, rhythm supports endurance, and familiar tracks can reduce perceived exertion.
Beyond physiology, music creates shared moments. It sets the atmosphere, builds anticipation and turns individual activity into collective experience.
For sports, wellness and fitness brands, this means music selection needs to align with brand values, customer experiences and emotional outcomes.
Well-chosen music increases workout intensity and duration, improves customer retention, strengthens brand recognition, creates community and cultural relevance, and opens new partnership models.
When delivered through properly licensed, data-informed systems, these outcomes become measurable and scalable.
Music also gives brands a way to stay culturally connected to their audience. The question for operators is how to use music strategically and legally.
This is especially important because the way brands approach music has changed significantly.
Early adoption in wellness, fitness and leisure centres often meant plugging in a Spotify playlist and hoping for the best.
Today’s leading sports and fitness innovators are far more sophisticated, curating music experiences that are brand-led, data-informed, tailored to specific audiences and workouts and fully licensed for commercial use.
This shift is being powered by specialist music technology platforms like Tuned Global, which works behind the scenes with brands to manage licensing, catalogue access, analytics and distribution at scale.
Rather than forcing sports brands to become music experts, these platforms allow them to offer legally compliant music in commercial environments, control curation across locations or content formats, and adapt music to different activities and intensities.
Through advanced APIs and centralised cloud infrastructure, operators can manage licensing, catalogue access and music governance at scale, while maintaining full creative control.
They also provide the reporting required by rights holders and integrate music into apps, devices, wearables and connected platforms. The result is music that feels intentional, on-brand and deeply embedded in the experience.
Music in action
Lululemon Studio and Mirror: At-home Fitness and Health
When Lululemon acquired Mirror, it marked a shift towards fully connected, at-home fitness where content, coaching and atmosphere converge.
Music plays a key role in making those workouts feel immersive and motivating, especially without a physical studio or shared space.
Instructors needed access to curated, commercially licensed music delivered consistently across live and on-demand workouts, while remaining compliant with music rights regulations.
Tuned Global provided Lululemon Studio with a branded playlisting app solution that enabled instructors to curate fully licensed music tailored to each workout.
Drawing from a licensed commercial catalogue and supported by usage reporting to rights holders, the system ensured compliance while giving instructors the flexibility to design high-energy, brand-aligned sessions.
The result was a seamless blend of movement, coaching and sound that makes digital workouts feel immersive and premium.
Psycle London: Performance Led Experiences

Con Raso
Boutique fitness studio Psycle London has built a loyal following by transforming workouts into performance-led experiences where music is central to the brand.
Each class is choreographed to sound, with instructors designing sessions that build emotional peaks and sustained intensity.
As Psycle expanded its digital and on-demand offering, it needed a way to give more than 70 instructors access to fully licensed commercial music while protecting the business from legal and reputational risk.
Tuned Global delivered a branded playlisting app that enabled Psycle’s instructors to search a cleared commercial catalogue by artist, genre or BPM, preview full tracks and build tailored playlists for classes ranging from high-intensity rides to strength and conditioning.
Behind the scenes, the music is delivered through secure API infrastructure integrated into Psycle’s own platform, with automated reporting to rights holders and support across label and publishing negotiations.
By combining creative flexibility with licensing governance, Psycle were able to scale its music-led experience across studio and digital environments without compromising on brand integrity, compliance or operational control.
Steezy: Movement and Music
Steezy, one of the world’s leading online dance platforms, sits at the intersection of sport, movement and music.
For dancers, music is not background sound. It defines timing, style and expression.
As Steezy scaled internationally, music became both its greatest asset and its biggest operational challenge. Delivering classes built around commercial tracks created both operational complexity and significant licensing risk.
Tuned Global provided the licensed music catalogue delivery infrastructure that enabled Steezy instructors to search a cleared catalogue, curate playlists tailored to specific classes, and prepare sessions using full commercial tracks.
The system ensured that music used across Steezy’s app and desktop platform was properly licensed and reported to rights holders, supporting global expansion without exposing the business or its creators to legal liability.
By combining instructor-friendly tooling with robust licensing governance, Steezy was able to continue growing its international dance community while keeping music at the centre of the experience.
A wider wellness ecosystem
For wellness, sports, fitness and leisure operators considering deeper music integration, a few principles stand out.
First, treat music as a product feature. It should support the outcome you want, whether that is higher intensity, calm recovery, emotional connection or brand recognition.
Second, get licensing right from day one. Using consumer streaming services in commercial environments exposes brands to legal and reputational risk.
For example, In 2019, more than 20 music publishing groups filed a $150 million copyright lawsuit against Peloton, alleging the company used more than 1000 unlicensed songs in its workout videos.
In another example, just last year the Federal Circuit and Family Court of Australia ordered a Sydney gym chain owner and five of his companies to pay more than $235,000 in damages and interest after operating multiple locations without a valid OneMusic licence.
Third, give creators freedom while maintaining brand control. Instructors, coaches and athletes bring personality, so give them tools to curate music safely within brand guidelines.
Last but not least, use data to refine the experience.
Track how music impacts engagement, completion rates and retention, because music is measurable. Finally, think cross-platform.
Your music strategy should work across physical venues, mobile apps, connected devices and on-demand content. Consistency builds trust.
What’s ahead for music as a performance tool
Music in wellness will become even more adaptive. As AI, biofeedback and real-time analytics become more embedded in fitness technology, music will increasingly respond dynamically to heart rate, pace or emotional state.
Early implementations in health and performance environments are already demonstrating how adaptive music can optimise outcomes.
As wearable technology and connected fitness continue to evolve, music will play an increasingly central role in shaping personalised experiences.
The infrastructure choices operators make now will determine how easily they can adopt these capabilities later. Those who invest early in licensed, data-informed music systems will be best placed to innovate without risk.
Music is a performance tool, a brand asset and a powerful lever for engagement. The examples above show that this applies at every scale, from a single boutique studio to a global combat sports brand.
The most successful innovators understand that when music and movement align, something special happens. With the right technology and licensing in place, that can scale.
About Con Raso, Managing Director of Tuned Global
Con Raso is an entrepreneur passionate about innovation, new technologies, and start-ups.
Over the last few decades he has focused on creating innovative mobile and online distribution models within the B2C entertainment market, enabling brands to utilise music as a marketing tool, via unique customer engagement strategies.
Being inherently well-versed in both technology and music, Con ensures our solutions are aesthetically pleasing, engaging and disruptive.
About Tuned Global
Tuned Global is the leading data-driven Cloud Music Platform that empowers businesses to integrate commercial music into their apps or launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, music intelligence and customisable white-label apps.
Our turnkey solutions for music, audio, and video, coupled with a broad ecosystem of third-party music tech integrations, make us the most comprehensive platform for powering digital music projects.
We streamline complexities in licensing, rights management, content delivery and music discovery, enabling rapid innovation and bringing new ideas to life.
Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, fitness, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.
For more information, visit www.tunedglobal.com.
News
Only 18% of UK workplaces have a menopause policy, survey finds

Only 18 per cent of UK workplaces have a menopause policy, according to a new survey. while half of 1,000 women said they feel supported during menopause at work.
The study found that 37 per cent of respondents said their employer does not provide any menopause support at all.
The new study, commissioned by women’s wellness specialist Serenova for International Women’s Day, surveyed perimenopausal, menopausal or post-menopausal women aged 30 or over.
Elle Sheppard, global head of marketing and communications at Serenova, said: “Mid-life women have so many pressures to face, the last thing they need is to feel like they have to suffer in silence at work, or worse, get forced into leaving a career they love due to a lack of support.
“Going through the menopause, including the peri and post stages, can last for years; this isn’t just a ‘flash in the pan’ day when you don’t feel your best, it’s a long period of lacking confidence, feeling exhausted and putting up with physical pain too.
The findings come as the government launched its gender pay gap and menopause action plan guidance on 4 March 2026, which will be compulsory for large businesses by April 2027.
Women working in healthcare and social services reported feeling the most supported, with 57 per cent agreeing they feel “somewhat” or “very” supported.
This was followed by public services, law and security at 53 per cent, education and non-profit at 52 per cent, and business, finance and professional services at 48 per cent.
Women working in retail reported feeling the least supported, at 44 per cent.
Among healthcare and social services workers, 36 per cent said their employer does not provide any support provisions, 22 per cent said their workplace had a menopause policy and 16 per cent said their employer provided counselling support. Just 7 per cent had access to menopause leave.
In comparison, 15 per cent of retail workers said their workplace had a menopause policy, 8 per cent had counselling and 10 per cent had menopause leave.
This was higher than in healthcare and social services, where just 7 per cent had menopause leave.
Regionally, workers in London reported feeling the most supported, with 59 per cent agreeing they feel “somewhat” or “very” supported, nine per cent higher than the national total.
The South East followed at 55 per cent, while Yorkshire and the Humber ranked lowest at 45 per cent.
Sheppard said: “Serenova was launched on International Women’s Day last year, with a goal of helping women take charge of their wellbeing so they can navigate this life phase with clarity and confidence.
“As we celebrate our first anniversary, we wanted to find out how supported women really feel, to shine a light on the reality of navigating midlife as a woman.”
Menopause
Non-hormonal menopause pill approved for NHS use

A new daily menopause pill approved for NHS use could bring relief to women with debilitating hot flushes and night sweats.
Around 500,000 women are expected to be eligible for the treatment, which experts say could help those unable to take hormone replacement therapy, or HRT.
The drug, fezolinetant, also known as Veoza, is a daily non-hormonal tablet designed to target the brain signals that trigger some of the most disruptive menopause symptoms.
In final draft guidance published today, the National Institute for Health and Care Excellence recommended the 45mg tablet for women experiencing moderate to severe hot flushes and night sweats.
More than two million women in the UK are thought to suffer these symptoms during menopause, often beginning during the earlier stage known as perimenopause.
For many, the effects are severe, disrupting sleep, affecting concentration and straining relationships. In some cases women are even forced to cut back on work.
An estimated 60,000 women in the UK are currently out of work or on long-term sick leave due to severe menopause symptoms, costing the economy roughly £1.5bn a year.
Research also suggests one in 10 women has left the workforce entirely because of a lack of support.
Entrepreneur3 weeks agoOura launches women’s health AI model
Insight2 weeks agoThe missing layer in the women’s health conversation
Insight3 weeks agoWomen’s HealthX launches in Boston this December to transform women’s health through data and science
International Women's Day 20262 weeks agoHow AI is shaping the future of women’s health
News2 weeks agoMenstrual health apps market tipped to reach US$13bn
Entrepreneur4 weeks agoMatresa raises £315k for maternal health platform
Hormonal health4 weeks agoEndometriosis-sufferer wins landmark tribunal case on workplace discrimination
Motherhood4 weeks agoState abortion bans linked to spike in maternal deaths, study finds














1 Comment